Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 1, 2017. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of November 30, 2017:
- Total issued ordinary shares: 5,371,899,706 (25 pence each).
- Shares held in Treasury: 453,205,950.
- Total voting rights: 4,918,693,756.
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,918,693,756) for compliance with Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (453,205,950) to calculate the correct denominator for interest notifications.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for performance metrics.